October 10, 2018
5 min watch
Save

Video: TIF treats GERD with less side effects

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PHILADELPHIA – In this exclusive video from the American College of Gastroenterology Annual Meeting, Skip Baldino, president and CEO of EndoGastric Solutions discusses the company’s recent success with transoral incisionless fundoplication for the treatment of GERD.

“With proton pump inhibitors, about 35% of patients are refractory to the PPIs, ie, they do not get symptom control,” he told Healio Gastroenterology and Liver Disease. “In the case of lap nissen, while it works extremely well, many people do not want to have that procedure because they do have de novo side effects. ... As a result, there’s a treatment gap where [EndoGastric Solutions] fits perfectly into.”

Baldino said the company recently debuted its third-generation device, Esophyx Z+, and more than 20,000 procedures have been performed since FDA approval. Additionally, data from a recent study found that approximately 80% of patients were off PPI therapy in 5 years after the procedure.

“There are now 80 peer-reviewed studies that showed that our procedure works, and it works well,” he said. “We don’t have the side effect profile that occurs with other anti-reflux interventions.”

Baldino said the company has also made progress on expanding reimbursement while securing more funding.

Disclosure: Baldino is employed by EndoGastric Solutions.